Trichostatin A (TSA)

Catalog No.S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Size Price Stock Quantity  
USD 247 In stock
USD 447 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 67 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Targets
HDAC [1]
(Cell-free assay)
~1.8 nM
In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 NWn4[3VRTnWwY4Tpc44hSXO|YYm= MVOwMlfPxE1? NIPPZnEzPGh? MXnleIhidm:u MkK1[Y5p[W6lZYOgSW5iSyCjY3X0fYxifGmxbjDhcoQhcW6lcnXhd4V{KEWQYVOgZYJ2dmSjbnPlJIlvKHSqZTD0c5RidCClZXzsJIx6e2G2ZTDhcoQh[XRidHjlJINmdGxic4Xy[oFk\Q>? MWqyOVc5PzB5OR?=
TE13 NULMPGFGTnWwY4Tpc44hSXO|YYm= M4CxVVAvO87:TR?= M{i3TFI1cA>? MUn1dE1z\We3bHH0[ZMhWkGVU1[1RUBt\X[nbB?= NFS1TVkzPTV5OU[2OS=>
TE13 M3\YSGFxd3C2b4Ppd{BCe3OjeR?= NILyWY0xNjQQvF2= MUWyOIg> NGPQcI1qdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:w MnLZNlU2Pzl4NkW=
MEFs NVLrfWZmTnWwY4Tpc44hSXO|YYm= NED2OHY2|ryP MXexOog> NVTobm13cW6lcnXhd4V{KHSqZTDFVGVEKGG2dHHjbI1mdnRuIGTpdkBl\WyrdnXyfUBidmRidHjlJIVn\mmlaXXuZ5khd2ZicHXk[ZN1[WxiZn;ycYF1cW:w NX63ToRHOjV2OEK2N|Q>
SW480  NY\yPYJsTnWwY4Tpc44hSXO|YYm= M2\CSlAvOc7:TR?= NV;RZZFqPDiq NEmwNmFFVVOR Mn3ldoV3\XK|ZYOgSW1V MX6yOVQ{PDl7Nx?=
PC3  MlvaSpVv[3Srb36gRZN{[Xl? NH;0T4gxNjIQvF2= MojwOFhp NHraS3hFVVOR NF35T2Fz\X[ncoPld{BGVVR? NYCyV2MxOjV2M{S5PVc>
SW480  MY\GeY5kfGmxbjDBd5NigQ>? NVH4PFBrOC5zzszN MYm0PIg> NGXGOXhFVVOR M1PPUIF1fGWwdXH0[ZMhcW64YYPpc44h[W6mIH3p[5JifGmxbh?= NIjmNo8zPTR|NEm5Oy=>
PC3  NFLG[HdHfW6ldHnvckBCe3OjeR?= NGnBS5MxNjIQvF2= NX7ZTmpPPDiq MXTEUXNQ MlXSZZR1\W63YYTld{Bqdn[jc3nvckBidmRibXnndoF1cW:w MV2yOVQ{PDl7Nx?=
SW480  NYjSZ4J5TnWwY4Tpc44hSXO|YYm= MY[wMlHPxE1? MkTpOFhp NUm3[INOTE2VTx?= MV7pcoR2[2W|IHnuZ5Jm[XOnIH;mJGhFSUNzIHHu[EBJTEGFMjDvckBUdHWpIHflcoV{KHC{b33veIVz MlrKNlU1OzR7OUe=
PC3  M1XBfGZ2dmO2aX;uJGF{e2G7 M2D6blAvOc7:TR?= NVXaTGU4PDiq M3uzemROW09? NGrkdoVqdmS3Y3XzJIlv[3KnYYPlJI9nKEiGQVOxJIFv\CCKRFHDNkBwdiCVbIXnJIdmdmW|IIDyc41wfGW{ NH\QNnQzPTR|NEm5Oy=>
A431 NVHD[G1TSXCxcITvd4l{KEG|c3H5 M136clIwOTBxNUCvNVAxdk1? NHPoV5U1QGh? NHvMfFNFVVOR NUHFW3VHcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4To M17jTFI2OzdzME[5
A431 NFL3VIpHfW6ldHnvckBCe3OjeR?= MXS1NI5O MU[yM|YwOTJxMkTo MWrEUXNQ NVjFU4Zm[WO2aY\heIV{KHB{MTDhcoQhcW6qaXLpeJMhSVSIMzDlfJBz\XO|aX;u M1nVUVI2OzdzME[5
MDA-MB-231 M2j3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rxVVAuPjBybl2= MUSyOIg> MnzTSG1UVw>? MVHJR|UxKG:oIEGwNI5O NXvCPINNOjVzOUK3NlE>
MCF7 M4HjNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrRSlcxNTZyMH7N NYDkTG57OjSq MWLEUXNQ M1:zSmlEPTBib3[gO|VvVQ>? M{X3NFI2OTl{N{Kx
SKOV-3 M2Ltbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYexMVEx|ryP NW\1O3NjOjSq NXTS[lZ5TE2VTx?= MWPJR|UxKG:oIEWuOu69VQ>? M2jqUFI2OTZ7NEmx
A549 MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFP4d|YyNTFyzszN MlfsNlRp MYHEUXNQ NUXL[5FGUUN3MDDv[kA{NjMQvF2= MX:yOVE3QTR7MR?=
SKOV-3 MkntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzrNE4yNTIQvF2= NEHiO441QGh? NIHyTXVFVVOR MYHJR|UxKG:oIECuO:69VQ>? MnjINlUyPjl2OUG=
A549 NVzlZpIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\I[VAvOS1zzszN MXK0PIg> MY\EUXNQ M4T0bWlEPTBib3[gNE4zQM7:TR?= NWPmZ4hSOjVzNkm0PVE>
SKOV-3 MoXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXRZmxMOC5yMT2wMlnPxE1? M1nJRlczcA>? Mkn6SG1UVw>? NFL0cm5KSzVyIH;mJFAvOzMQvF2= M{PMZlI2OTZ7NEmx
A549 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7xNE4xOS1yLkpOwG0> NIrHZoE4Omh? MX7EUXNQ MVvJR|UxKG:oIECuNFbPxE1? NVTVZ2dCOjVzNkm0PVE>
HeLa M3fFXGZ2dmO2aX;uJGF{e2G7 M1v1VFI2OG6P MYWxOog> NGfVbI1FVVOR MnjkbY5kemWjc3XzJGN[WDGDMTDtVm5CKGW6cILld5Nqd28EoB?= MYSyOVEyPjZ6OB?=
CNE2 M1rMdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;BdJpuOTByLU[wNI5O MWCyOE81QC95Mni= NXvMN497cW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTD0bY1mNSCjbnSg[I9{\S2mZYDlcoRmdnRibXHucoVz NY[2dGxFOjR7Nkm5NFE>
PC3 Ml7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnNNVAxNTFyMEDuUS=> NWfYeZBwOjSq NHT4dVVKSzVyIH;mJFMxOG6P M4raN|I1QDV2NkW4
LNCaP M3vkZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTRXWJWOTByLUGwNFBvVQ>? MYGyOIg> M2rkTmlEPTBib3[gN|Axdk1? NGjyU3gzPDh3NE[1PC=>
HeLa  NXrJfYlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XkPVLPxE1? M1LK[FQ5cA>? NV:5U|NP\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIFjd3W2IEK1KS=> M4XONVI1QDR4MUO1
HMEC-1  Ml\rSpVv[3Srb36gRZN{[Xl? NITRVYY{ODCwTR?= NXXpc4hYOjSq M1GyfIlv[3KnYYPld{BmgHC{ZYPzbY9vKG:owrDWSWdHWjQEoH3SUmE> MX:yOFcyODZ|MR?=
HeLa NFHqdppHfW6ldHnvckBCe3OjeR?= M2\iN|FuVQ>? NVfRSlNtOC53aB?= MX3hZo9tcXOqZYOgeIhmKHSxdHHsJGhFSUNiYXP0bZZqfHl? MmPlNlQ4ODd2N{S=
ACP02 MlKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nWPFI2OC9|NUCvOVAxdk1? NWTPPYNkOjSq M4Dl[4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDv[kBieHC{b4jpcYF1\Wy7IEewxsAmKGG2IEK1NOKhdk1? NInmSm0zPDZ4OEW0Oy=>
ACP03 MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIi4N2wzPTBxM{WwM|UxOG6P M37UVVI1cA>? Mnv4[IVkemWjc3XzJINmdGxidnnhZoltcXS7IH;mJIFxeHKxeHntZZRmdHliN{FCpEUh[XRiMkWwxsBvVQ>? MmHMNlQ3Pjh3NEe=
U87 GBM NU\vXm9FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7VNVAxNzNyMD:1NFAhdk1? NGn6UFE4OiCq MWCxNFAmKGW2aHHuc4w> NF;6fJpz\WS3Y3XzJI1m[W5iY3XscEBvfW2kZYKgZpkhOzFuIEW0MEBidmRiNUlCpEU> Mk\DNlQ1PjR6NEG=
U87 GBM NVy1ZYM4TnWwY4Tpc44hSXO|YYm= NFracJEyODBxNUCwJG5u MnjEOFghcA>? M360blExOCViZYToZY5wdA>? M2rW[mlv\HWlZYOgV4Vv\XOlZX7j[U1NcWunIFHseIVz[XSrb37zJIlvKE63Y3zlZZIhVW:{cHjvcI9ogQ>? MXmyOFQ3PDh2MR?=
RPE MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIGwSGExNjJxMD60M|AvQC9zIN88US=> NFixfFYzPC92OD:3NkBp MVTEUXNQ NF7T[HNqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBjgSClZXzsJIN6[2ynIHHydoV{fA>? MlnRNlQ1PTZ4MEK=
HT29  NFzBSWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnIdm5uOThyIH7N MlzEO|IhcA>? MYnJR|UxKG:oIEG4NEBvVQ>? M4PaTlI1OzZ6Mk[1
hMSCs NUKzZWt5TnWwY4Tpc44hSXO|YYm= MV[2MlI2KG6P NVviSVB6OjRiaB?= NWjxemM{TE2VTx?= NGS5eW1{fGGkaXzpfoV{KEirc4TvcoUhSWOndInsZZRqd25iYX7kJJRp\SCHeIDy[ZN{cW:wIH;mJHBtfXKrcH;0[Y51KEenbnXz M2\TWlI1OzF{M{W2
Huh7  NWLQSVBPTnWwY4Tpc44hSXO|YYm= NXK1NlRWOC5zL{CuOU8yNjBizszN MYeyOIg> NUW0WlB4e3WycILld5NmeyC\VFjER|Ih\2WwZTDlfJBz\XO|aX;u M3HCO|I1OjZ7Nkey
SKOV3 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFuyc5QxNjB3LUKg{txO MV2xNE8zPC92ODDo MnfxSG1UVw>? NX\WOYpNdWWmaXH0[ZMh\3Kxd4ToJIFzemW|dDDpckBiKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NVHHbXRxOjR{MkO4NFE>
A2780 NV\MTnNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7tRXIxNjB3LUKg{txO M{W0VFExNzJ2L{S4JIg> M2X6OWROW09? NXLmcGFVdWWmaXH0[ZMh\3Kxd4ToJIFzemW|dDDpckBiKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NG\1NZkzPDJ{M{iwNS=>
SRA01/04  M1Xs[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUWwMlIh|ryP MYi0PEBp NXfsUpdWTE2VTx?= NXXSWlFMe3WycILld5NmeyClZXzsJJBzd2yrZnXyZZRqd25idHjyc5VocCC|dYDwdoV{e2mwZzD0bIUhWEl|Sz;Bb5QtKHB|OF3BVGsh[W6mIFXST|EwOiC|aXfuZYxqdmdicHH0bJdigXN? M4XzR|I1OTV5OEe4
HLEB3 MoTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXRUpgxNjJizszN MnnxOFghcA>? MXjEUXNQ NGeyZY1{fXCycnXzd4V{KGOnbHygdJJwdGmoZYLheIlwdiC2aILveYdpKHO3cIDy[ZN{cW6pIITo[UBRUTONL1HreEwheDN6TVHQT{BidmRiRWLLNU8zKHOrZ37hcIlv\yCyYYToe4F6ew>? MkTkNlQyPTd6N{i=
SRA01/04  MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYCwMlQwOC56IN88US=> NIK5V2w1QCCq MXfEUXNQ MkDobY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MYqyOFE2Pzh5OB?=
HLEB3 MknoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;afowxNjRxMD64JO69VQ>? MWK0PEBp NV\zRodNTE2VTx?= MlXPbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MVmyOFE2Pzh5OB?=
HCT116 M3XK[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1mzd|AvOiEQvF2= M3nYSlEzKGh? M1PPOoVvcGGwY3XzJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomgdoFlcWG2aX;u NHiwNHAzPDF{MkKzNS=>
CA46 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPON{83NzF{L{K0M|Q5KG6P MkTyOFghcA>? MXXpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGG2IEK0JIFv\CB2ODDuUeKh NH\QbJkzPDB4NEm1NS=>
PMNs NX\QdYpoTnWwY4Tpc44hSXO|YYm= NHrUVW0{OCCwTR?= NGTQdW01QCCq MWXpcohq[mm2czDl[oZmem:leYTvd4l{NCCKRFHDJIFkfGm4aYT5JIFv\CCUYXOgZYN1cX[rdIm= M1f2ZVI{QTh6NkG3
H1299 MnLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkL1NeKh|ryPwrC= MoPENlQwPDhxN{KgbC=> Morx[ZRp[W6xbB?= M2frZolv[3KnYYPld{Bk\WyuIHTlZZRpKGGodHXyJFI1cA>? MYeyN|kyPjZyOR?=
A549 NUnOT4JDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTzT3ZNOC5{NT:wMlUwOSEQvF2= MVOyOE81QC95MjDo NHG0cFNmfGijbn;s NYTlUGRUcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJIlvKGOxbnPlcpRz[XSrb36gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NVu1SmgyOjN6Nke5PVE>
H1299 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jqfFAvOjVxMD61M|Eh|ryP M2TNR|I1NzR6L{eyJIg> M3PwVYV1cGGwb3y= MXvpcohq[mm2czD0bIUh[2WubDDndo94fGhiaX6gZ49v[2WwdILheIlwdiCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz M3\uZ|I{QDZ5OUmx
A549 NX7QRnBDSXCxcITvd4l{KEG|c3H5 Mlf2NE42NzFizszN NWTRXXQ3PDhiaB?= MYPleIhidm:u MY\pcoR2[2W|IHPlcIwh[XCxcITvd4l{ NX\HT2R4OjN6Nke5PVE>
H1299 NWTvdFRoSXCxcITvd4l{KEG|c3H5 NY\2coZoOC53L{Gg{txO NFvqZXA1QCCq MlTz[ZRp[W6xbB?= NXK1bZA4cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NIfKd4wzOzh4N{m5NS=>
SUM149PT M4n6NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVuyM|cvPS9zMDFOwG0> M2\wOFQ5KGh? MUjEUXNQ M{\ZPYlv\HWlZYOgZ4VtdCCmZXH0bEBifCB{IN88UUBqdnOnboPpeIl3\Wy7 MnjWNlM4QTJ4M{i=
SUM190PT MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vTflUxNzFyMD:yOVAhdk1? NV\ZeJluPDhiaB?= MU\EUXNQ M4fXcIlv\HWlZYOgZ4VtdCCmZXH0bEBifCB3MDDuUUB{\W6|aYTpeoVtgQ>? NFzhZlQzOzd7Mk[zPC=>
HCT1 NYf6SXlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPaW4gxNjJxMT6wM|UvOCEQvF2= NFXRRVQyOi9{ND:zOk81QCCq NYHDTZZ4cW6mdXPld{Bk\WyuIHTlZZRpKGmwIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> M1zZXFI{PzdyMECw
Lovo NUfC[FVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nE[VAvOi9zLkCvOU4xKM7:TR?= NFLubW0yOi9{ND:zOk81QCCq NEixW|RqdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> M4rpTVI{PzdyMECw
AGS NXLpUJNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmT3NE4xOTVvMTFOwG0> MnjSO|IhcA>? MlL3bY5lfWOnczDj[YxtKGSnYYToJINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= MnP5NlM4PDVyMkS=
Huh7 NEnieVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnj0NUDPxE1? MX2yOEBp MV\EUXNQ M2DPVpJm\HWlZYOgZYJwfXRiMkClJJZq[WKrbHn0feKh NF:2Sm0zOzZ2M{mzNy=>
ECC1 MUnGeY5kfGmxbjDBd5NigQ>? MVK1NFAhdk1? M{L3XFUh\A>? Mk[2SG1UVw>? MkPzbY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? NYn2UVdoOjN3M{C3Olk>
HEC1A NWDmeZFITnWwY4Tpc44hSXO|YYm= M4e3SVUxOCCwTR?= MVi1JIQ> M1rzZmROW09? NULNXoQ1cW6mdXPld{BNOUODTdMg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2NUG8YVO= MnqxNlM2OzB5Nkm=
EN1 M{PnbmZ2dmO2aX;uJGF{e2G7 MmraOVAxKG6P NFrOdIU2KGR? MnfOSG1UVw>? MWfpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? NHSwbZkzOzV|MEe2PS=>
MFE296 MlzrSpVv[3Srb36gRZN{[Xl? MmPSOVAxKG6P NUfEXod2PSCm Mn;kSG1UVw>? M2fnZolv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF Ml6zNlM2OzB5Nkm=
HASMCs Mo\kSpVv[3Srb36gRZN{[Xl? MkPSNE02ODBibl2= MWG2JIQ> MVLkc5dvNXKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCKQVTDJIFv\CClZXzsJJZq[WKrbHn0fS=> M3LLUVI{PTF6NE[3
U373 NULG[FRuTnWwY4Tpc44hSXO|YYm= NIizdYQxNjJ3L{CuOU8yKM7:TR?= M2W3clI1KGh? NI[4fZRqdmO{ZXHz[ZMhWFJvQjDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFVCgmGmQx?= MYWyN|Q4PDF5MR?=
ARN8  MYPGeY5kfGmxbjDBd5NigQ>? M135XVAvODVvMjFOwG0> NET2PWEzPCCq NVq2UXJHemWmdXPld{B1cGViaX7keYN1cW:wIH;mJJA2Oy2mZYDlcoRmdnRiZ3Xu[ZMh[nliToX0cIlvNTN? NFSzSIUzOzR5MEW0NC=>
MCF7 NXjUZpV3TnWwY4Tpc44hSXO|YYm= MYiwMlA2NTJizszN MmDjNlQhcA>? MkS4doVlfWOnczD0bIUhcW6mdXP0bY9vKG:oIIC1N{1l\XCnbnTlcpQh\2WwZYOgZpkhVnW2bHnuMVM> NEfqd3ozOzR5MEW0NC=>
H1299  NIH3bWxHfW6ldHnvckBCe3OjeR?= MVuwMlM{6oDVMdMgxtVO MmHrNlQwPDhiaB?= NWCybFh6TE2VTx?= MYDpcoNz\WG|ZYOgSU1k[WSqZYLpckBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7 MontNlM1PjF7N{W=
H1299 Moj4SpVv[3Srb36gRZN{[Xl? MWCwMlUh|ryP NXTzbmtiPDhiaB?= M1XoUmROW09? MX7pcohq[mm2czD0bIUhdWmpcnH0c5J6KHCxdHXueIlidCClb33ibY5mKHerdHigd4ltcWKrbnnu NYDOcYRlOjN2NkG5O|U>
H1299 NWH6S5ltTnWwY4Tpc44hSXO|YYm= NH;vfIIxNjVizszN MVW0PEBp NIjmZ4dFVVOR NVzXdZo{cW6qaXLpeJMhfGinIHnueoF{cX[nbnXzd:KhKGOxbXLpcoUhf2m2aDDzbYxq[mmwaX6= NFX5W|AzOzR4MUm3OS=>
MG-63  Mn\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NImwZ5cxNjNizszN MU[xNk06PiCq NHfOWZNFVVOR NYTWcXFucW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=> MoS3NlM1PTF6MUe=
LM8 M2e0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLQc3dqOC5|IN88US=> MoW2NVIuQTZiaB?= M{Lsd2ROW09? MUfpcohq[mm2czD0bIUh[2WubDDndo94fGhiY3:teJJm[XSvZX70JJdqfGhibXX0[o9zdWmw MViyN|Q2OThzNx?=
K562 NFX6NI5HfW6ldHnvckBCe3OjeR?= NV7TfZo1OC53IN88US=> M1LZflI1KGh? MmDw[ZRp[W6xbB?= NEXwTpRl\WO{ZXHz[ZMhfGinIHXufplu\SCjY4Tpeol1gSCxZjDISGFEeyClbz30doVifG2nboSge4l1cCCldYLjeY1qdg>? NEfPVnAzOzR|MEm1Oy=>
HEL M3raN2Z2dmO2aX;uJGF{e2G7 NVrIUWE3OC53IN88US=> MWGyOEBp NHL0NVlmfGijbn;s MVXk[YNz\WG|ZYOgeIhmKGWweont[UBi[3Srdnn0fUBw\iCKRFHDd{Bkdy22cnXheI1mdnRid3n0bEBkfXKldX3pci=> MViyN|Q{ODl3Nx?=
HL60 NVzHU4N7SXCxcITvd4l{KEG|c3H5 MVexJO69VQ>? M2m3[FI1KGh? NYPUbZRKcW6mdXPld:Kh[2WubDDk[YF1cA>? NGq4XXYzOzRyMEWxPS=>
KG1 MkTnRZBweHSxc3nzJGF{e2G7 MkT1NUDPxE1? MkjXNlQhcA>? M4rt[Ilv\HWlZYRCpINmdGxiZHXheIg> M{f3SVI{PDByNUG5
Kazumi NXvFOZI5SXCxcITvd4l{KEG|c3H5 NFT2UlIyKM7:TR?= NUDOPFJjOjRiaB?= MVTpcoR2[2W|wrDj[YxtKGSnYYTo NFf1b|UzOzRyMEWxPS=>
K562 MUHBdI9xfG:|aYOgRZN{[Xl? M2LJPFEh|ryP MWSyOEBp MkDRbY5lfWOnc9MgZ4VtdCCmZXH0bC=> MoHWNlM1ODB3MUm=
THP1 Ml:5RZBweHSxc3nzJGF{e2G7 MWmxJO69VQ>? MXOyOEBp M2DER4lv\HWlZYRCpINmdGxiZHXheIg> M{nXUFI{PDByNUG5
SH-SY5Y NHXjSHFHfW6ldHnvckBCe3OjeR?= M3e3RlI2OCCwTR?= NUDoTWlJOTZiaB?= NEfFbVJkcGGwZ3XzJIV5eHKnc4Ppc44heGG2dHXyckBw\iCpZX7ld{Bqdn[xbI\l[EBqdiClaH;s[ZN1\XKxbDDzfY51cGW|aYOsJJVxfGGtZTDhcoQh\W[obIX4 MkXVNlM{OjZ2MkK=
HEK293 M3TvOGZ2dmO2aX;uJGF{e2G7 MofvNUDDvU4EoB?= NFjmT3QyQCCqwrC= MnPabY5pcWKrdIOgeIhmKGujbHnybY4uPy2vZXTpZZRm\CC{ZXPyeYl1dWWwdDDv[kB{gW6yaHnsbY4uOSCjZ3fy[YdifGW|IHnueI8h[WepcnXzc41mew>? NV;4cndNOjN{OES4OFg>
HTK MorzSpVv[3Srb36gRZN{[Xl? MmnlOFAxKG6P NFvmWlc4OiCq NH33XZlqdmirYnn0d{BVT0ZvzsNihLNKdmS3Y3XkJG16d2[rYoLvZoxie3RiRHnm[oVz\W62aXH0bY9v NWflVJd7OjN{OESwNFI>
HTK MUjGeY5kfGmxbjDBd5NigQ>? MlryNVAxNThyMH7N M17zW|czKGh? NEixdZRjdG:la4OgWGdHNc7{4pETTY5lfWOnZDDSU3Mh[W6mIFiyU|LDqEGlY4XteYxifGmxbh?= MWmyN|I5PDByMh?=
Caco-2  NHnZUHNHfW6ldHnvckBCe3OjeR?= NXzXc4FVOSEEtV5CpC=> MmnCNlQhcA>? NFnZWFRl\WO{ZXHz[ZMhW0WUVDDwdo91\WmwIHX4dJJme3Orb36= NHy1fXczOzF7NUC3NC=>
HeLa NF3FNGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjDfYkyODBibl2= NGnINZAzPCCq Mo\qSG1UVw>? MV7JR|UxKG:oIEGwNI5O NI\WflczOzF4NUe0PC=>
HeLa MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVq0NEBvVQ>? NImxTI41QCCq NGT5PIVFVVOR M1;qNWlEPTBib3[gOFBvVQ>? MoPPNlMyPjV5NEi=
HeLa MkG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjTZ4lbOjBibl2= NUeyZ4MzPzJiaB?= M{LxT2ROW09? M{\TXWlEPTBib3[gNlBvVQ>? NWHJTXBTOjNzNkW3OFg>
HeLa MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\UNVAwOzBxNUCgcm0> MnvUO|IhcA>? M{jleWROW09? M{LjfYlv[3KnYYPld{B1cGViboXtZoVzKG:oIF3NVEAp|pUQqH2pJIxwe3NiY3XscJMh\G:|ZTDk[ZBmdmSnboTsfS=> MlrqNlMyPjV5NEi=
MDA-MB-231 M4PCd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjSTFgzPS12MECgcm0> MUG0PEBp NFL3RXpKSzVyIH;mJFI3Oy5{bl5CpC=> NHvJeZUzOzB3NUG5PC=>
MCF-7  M1XOZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXiyOU01ODBibl2= NWjLOoxiPDhiaB?= MorBTWM2OCCxZjCyNlAvPG6P MVKyN|A2PTF7OB?=
ECC-1  M3XW[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUmxNFAhdk1? NFLDOJYzPCCq M3\IOoV1cGGwb3y= Mkj6bY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIFxd3C2b4TpZ{BvfWOuZXmgeI8hOzVn MkO3NlMxOjh6MEO=
HEC-1A NX\xVmt5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILmVGwyODBibl2= NUnKNVN{OjRiaB?= NHTJR2NmfGijbn;s MUXpcoNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[gZZBweHSxdHnjJI52[2ynaTD0c{A{QSV? NFXaRlIzOzB{OEiwNy=>
NHAC-kn MoLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUCxNE8yODBxNUCwJI5O Mn64NVIhcA>? NV\6[HE3TE2VTx?= NWO5TZg1UUN3MDDv[kA2ODCwTR?= NF7XZlYzOzBzN{i3NS=>
A549 M{XZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHrRZVGOjVyIH7N NYj1OlNKPi15MjDo MVjEUXNQ NULUZ3Jw[2G3c3XzJIEh\3KnYYTldkBqdmirYnn0c5J6KGWoZnXjeEBkd22kaX7lJJdqfGhiVGjUJI9zKGW{bH;0bY5q[g>? NWXpc3BTOjJ7OUS3PFA>
MG-63 M1r1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUS3PHgzOzByIH7N MYixNkBp NFzpNZdFVVOR MWjpcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gPFYm NXKyZVJOOjJ5OUmzN|g>
MG-63 M3LJXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYizNFAhdk1? MkPJNlQhcA>? NV3OZW5lTE2VTx?= NFnDbpFqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPjdn MoftNlI4QTl|M{i=
MG-63 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYezNFAhdk1? NEnyOYg1QCCq NWq4O2hnTE2VTx?= MlLkbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFU3LQ>? M4q4OVIzPzl7M{O4
HL60  NGrOd2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfaNVUxNTN3MDDuUS=> NGP2cHYzPCCq NVrPeVRscW6lcnXhd4V{KGOnbHygZZBweHSxc3nzxsB4cGWwIHPvcoNmdnS{YYTpc45{KGirZ3jldkB1cGGwIEK1NEBvVQ>? NFKzb4UzOjd3M{ezPS=>
U937 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYmxOVAuOzVyIH7N NGC3fXMzPCCq MWfpcoNz\WG|ZYOgZ4VtdCCjcH;weI9{cXQEoIfo[Y4h[2:wY3XueJJifGmxboOgbIlocGW{IIToZY4hOjVyIH7N NGe4dYgzOjd3M{ezPS=>
SCC-6 MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7HNlAxNTN{MECgcm0> NHfFSmwyOi9{ND:0PEBp NUPBWG5bTE2VTx?= NWe2emtRcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hd2ZiU1PDMVYh[2WubIOgbY4h[SCmb4PlMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy NF;HOVUzOjV3MkOyNS=>
U87  NEHiPHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWf3T29UOTByLUOwNEBv\w>? MYCyOEBp MVfpcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gO|ImKCCjdDCyNFBv\w>? M2fJRlIzOjdyOES5
K562 NHG3TVlHfW6ldHnvckBCe3OjeR?= MkXvNUDPxE1? NGHXSIoyOiCq MoDCSG1UVw>? MUPlcohidmOnczD0bIUh\XiycnXzd4lwdiCxZjDSWW5ZOyCrbnT1Z4VlKGK7IEWtZZpiNUOmUh?= M4DoSVIzOTd7MUm4
Reh Mln2SpVv[3Srb36gRZN{[Xl? MYmwMlMwOSEQvF2= M{H0XVEzKGh? NVzPZ2ZbTE2VTx?= MmO1[Y5p[W6lZYOgeIhmKGW6cILld5Nqd25ib3[gVnVPYDNiaX7keYNm\CCkeTC1MYF7[S2FZGK= M1K2WVIzOTd7MUm4

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
EGFR / STAT3 ; 

PubMed: 31289542     


Expression of EGFR and STAT3 in PC3 cells treated with TSA. PC3 cells were plated in 6-cm dishes, and 0.25, 0.5 or 1 µM TSA was added for 24 h. DMSO was added into the control group wells. Cells were collected and lysed with lysis buffer and the protein expression analyzed via western blotting.

Cyclin D1 / CDK6 / CDK4 / p-RB / RB; 

PubMed: 31289542     


Expression of cyclin D1, CDK6, CDK4 and RB, and the phosphorylation of RB, was detected in PC3 cells treated with TSA for 24 h. 

MMP-1 / MMP-3 / MMP-13 / TIMP-1; 

PubMed: 27431944     


Chondrocytes were pretreated with increasing concentrations of TSA for 2 h, followed by stimulation with 5 ng/ml IL-1β for 24 h.

Acetyl-H3 (Lys27) / H3 (96C10) / Acetyl-H4(Lys8) / H4(L64C1); 

PubMed: 27431944     


Chondrocytes were treated with increasing concentrations of TSA for 24 h.

α-H3Ac / α-H4Ac / α-H3K9Ac / α-H3K9 S10 / α-H3K4 me / α-H3K4 me2 / α-H3K9 me2; 

PubMed: 23802098     


Histone acetylation occurs directly at the promoter region of IL-23R. The ChIP assay demonstrates that TSA treatment results in an increase in the acetylation of histone H3 and H4. A549 cells were cultured in the presence or absence of TSA (250 ng/mL) for a period of 24 h. Subsequently, a ChIP assay was performed using the following antibodies; pan acetyl-histone H3 (H3Ac), pan acetyl-histone H4 (H4Ac), acetyl-histone H3 Lys 9 (H3K9Ac), acetyl-histone H3 Lys 9/14 (H3K9/14ac), acetyl-histone H3 Lys 9 phosphoSer10 (H3K9S10), methyl-histone H3 Lys 4 (H3K4Me), di methyl-histone H3 Lys 4 (H3K4Me2), and di methyl-histone H3 Lys 9 (H3K9Me2). Input DNA serves as a positive control as recommended by the manufacturer (Diagenode). A no antibody control was included to test for non-specific binding (UT, untreated; TSA, Trichostatin A).

31289542 27431944 23802098
Immunofluorescence
α-C/EBPβ / α-HP1α ; 

PubMed: 21122806     


3T3-L1 preadipocytes were grown on coverslips for three days and induced to differentiate by treatment with MDI (48 h) in the presence of vehicle (-TSA) or 87 nM Trichostatin A (+TSA). Under these experimental conditions: A-H Cells were fixed and permeabilized in cold methanol, subjected to IIF with the indicated antibodies, and nuclei were counterstained with DAPI. Scale bar, 5 μm. 

α-HDAC1 ; 

PubMed: 29045501     


MCF-7 cells were treated with indicated concentrations of trichostatin A (optical sections E-H, respectively) for 12 hours, fixed, permeabilized and optical sections were obtained by laser scanning confocal microscopy. Fluorescence signal for HDAC1 is shown in green (left panels), DAPI staining is shown in blue (middle panels), and merged optical sections are shown in the right panels.

α-tubulin / acetylated histone 3; 

PubMed: 27957719     


Immunocytochemistry for acetylated α-tubulin (red) and acetylated histone 3 (green) on N2a cells treated with 1 μM TSA, ACY-738, and ACY-775.

21122806 29045501 27957719
Growth inhibition assay
Cell viability (A549 cells); 

PubMed: 27571418     


Cytotoxicity of histamine determined by MTT assay in A549 cells.

Cell viability (MDA-MB-231 cells); 

PubMed: 27548148     


The human breast cancer cells (MDA-MB-231) were incubated with various concentrations of TSA (0–300 nM) for 24 h. Cell viability was measured by WST-8.

Cell viability (PC3 cells); 

PubMed: 31289542     


PC3 cells were plated in a 96-well plate and treated with different doses of TSA (0, 0.25, 0.5 and 1 µM) for 72 h; an MTT assay was used to measure the effects of TSA on PC3 cell proliferation.

27571418 27548148 31289542
In vivo Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research:

[1]

+ Expand
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM
  • Incubation Time: 96 hours
  • Method:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • Formulation: Dissolved in DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: Injection s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 302.4
Formula

C17H22N2O3

CAS No. 58880-19-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03901053 Not yet recruiting Device: Reaktiv AFO|Device: PhatBrace AFO Foot Injuries and Disorders Jason Wilken|Minneapolis Veterans Affairs Medical Center|Walter Reed National Military Medical Center|Henry M. Jackson Foundation for the Advancement of Military Medicine|Center for Veterans Research and Education|University of Delaware|Johns Hopkins Bloomberg School of Public Health|University of Iowa June 2019 Not Applicable
NCT03887650 Recruiting Drug: Liposomal Bupivicaine 1.3%|Drug: Bupivacaine 0.5% Post-operative Pain|Total Shoulder Arthroplasty|Osteoarthritis of the Shoulder|Pain Management Hartford Hospital January 14 2019 Phase 4
NCT03838926 Recruiting Drug: Trichostatin A Relapsed or Refractory Hematologic Malignancies Vanda Pharmaceuticals September 27 2018 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • Answer:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Trichostatin A (TSA) | Trichostatin A (TSA) supplier | purchase Trichostatin A (TSA) | Trichostatin A (TSA) cost | Trichostatin A (TSA) manufacturer | order Trichostatin A (TSA) | Trichostatin A (TSA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID